Nyxoah (NASDAQ:NYXH) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Nyxoah (NASDAQ:NYXH) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium. “

Separately, Cantor Fitzgerald restated an overweight rating on shares of Nyxoah in a research note on Tuesday, December 21st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Buy and an average price target of $42.00.

Shares of Nyxoah stock opened at $22.98 on Wednesday. Nyxoah has a 12-month low of $19.05 and a 12-month high of $37.00. The stock’s 50 day moving average is $21.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.68 and a quick ratio of 6.67.

Large investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new position in Nyxoah in the third quarter valued at about $214,000. Credit Suisse AG bought a new position in Nyxoah in the third quarter valued at approximately $221,000. Jane Street Group LLC bought a new position in Nyxoah in the third quarter valued at approximately $228,000. Evolutionary Tree Capital Management LLC bought a new position in Nyxoah in the third quarter valued at approximately $1,126,000. Finally, Monashee Investment Management LLC bought a new position in shares of Nyxoah during the 3rd quarter worth approximately $1,719,000. 10.35% of the stock is currently owned by hedge funds and other institutional investors.

Nyxoah Company Profile

Nyxoah SA, a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea.

Featured Article: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Get a free copy of the Zacks research report on Nyxoah (NYXH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.